HDAC inhibitors are an emerging class of anticancer agents that includes the FDA approved drugs vorinostat, romidepsin, and belinostat for the treatment of cutaneous and/or peripheral T cell lymphoma, and panobinostat for the treatment of multiple myeloma. Here, HDAC9 is linked to plasma cell myeloma.